PL - Seizure-Busting Rally and Cancer Shockwaves- These Stocks Are Heating Up into the Close

2025-09-08 14:53:11 ET

DENVER, Colo., Sep 08, 2025 ( 247marketnews.com )- As markets head into the final stretch of today’s session, all eyes are on a select group of stocks delivering outsized moves on game-changing clinical trial updates and growing institutional interest. These names are lighting up watchlists for the close and after-hours session.

Rapport Therapeutics (NASDAQ:RAPP) is commanding Wall Street’s attention today after reporting positive topline results from its Phase 2a trial for RAP-219, a first-in-class therapy targeting drug-resistant focal onset seizures. The data speaks volumes:

• 77.8% reduction in clinical seizures ( p=0.01 )
• 24% of patients achieved complete seizure freedom ( p<0.0001 )

Dr. Jacqueline French of NYU Langone called it “the first time a novel antiseizure medication was evaluated using an objective biomarker of seizure activity.” With a Phase 3 registrational trial now in sight for 2026, the biotech is breaking out. Expect continued interest in after-hours trading as institutional buyers circle, but keep an eye on a potential funding deal.

Lixte Biotechnology (NASDAQ:LIXT) is surging after momentum builds around LB-100, its lead PP2A inhibitor dubbed a “cancer power-up” by oncologists. The drug is drawing attention for its ability to force tumors into lethal activation while supercharging chemo and immunotherapy response.

Currently in trials for ovarian clear-cell carcinoma with GlaxoSmithKline (NYSE:GSK) , LB-100 is positioned as a potential paradigm shift in immuno-oncology, with synergy noted in immune checkpoint blockade and tumor microenvironment remodeling. Watch for conference updates or data drops in the coming weeks.

Sentage Holdings (NASDAQ:SNTG) is seeing speculative flows late in the session, despite no fresh company-specific news. Known for past parabolic intraday spikes, the stock is likely riding sympathy momentum from other micro-cap runners. Traders are eyeing key resistance at $1.25, where a breakout could trigger after-hours algo interest.

Microbot Medical (NASDAQ:MBOT) is quietly building steam ahead of expected updates on its Self-Cleaning Shunt (SCS) system, designed to reduce device occlusions in brain and spinal procedures. With recent mentions in surgical device symposiums and a history of low-float volatility, MBOT is one of the under-the-radar movers on today’s biotech sweep.

Acrivon Therapeutics (NASDAQ:ACRV) is rebounding off a multi-month low, riding optimism around its precision oncology pipeline, including ACR-368, a selective CHK1/2 inhibitor. The stock appears to be accumulated ahead of expected Q4 pipeline updates.

Dianthus Therapeutics (NASDAQ:DNTH) is catching a bid amid chatter about possible upcoming catalysts in its monoclonal antibody programs targeting complement-mediated diseases. While the company has kept a low profile since its IPO, speculative biotech investors are looking for low-float names with immune disease exposure.

Power Hour Takeaway

Today’s action reflects a clear appetite for asymmetric risk , particularly in small-cap biotech and speculative healthcare names. Rapport’s seizure data is the clear market mover, while LIXT is building a longer-term thesis around tumor microenvironment manipulation.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies. Please review our Full Disclaimer https://www.247marketnews.com/disclaimer/ . Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT and 247marketnews.com disclosure information. 247 has been paid by Microcap Advisory for providing ongoing LIXT market outreach and other services.

The post Seizure-Busting Rally and Cancer Shockwaves— These Stocks Are Heating Up into the Close appeared first on 24/7 MarketNews .

For further details see: